HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

omega-N-Methylarginine (NG Monomethyl L Arginine)

Subscribe to New Research on omega-N-Methylarginine

A competitive inhibitor of nitric oxide synthetase.

Also Known As:

NG Monomethyl L Arginine; L-NG-Monomethyl Arginine; N(G)-Methylarginine; N(G)-Monomethyl-D-Arginine; N(G)-Monomethylarginine; N(omega)-Monomethyl-L-Arginine; Arginine, L-NG-Monomethyl; L Monomethylarginine; L NG Monomethyl Arginine; omega N Methylarginine; D-NMMA; L-Monomethylarginine; L-NMMA; NG-Monomethyl-L-Arginine

Networked: 528 relevant articles (25 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10808

Experts

1.	Schmieder, Roland E: 5 articles (10/2014 - 10/2004)
2.	Branco, Luiz G S: 4 articles (09/2008 - 02/2002)
3.	Bech, Jesper N: 3 articles (09/2015 - 01/2014)
4.	Pedersen, Erling B: 3 articles (09/2015 - 01/2014)
5.	Tota, B: 3 articles (11/2014 - 05/2001)
6.	Schneider, Markus P: 3 articles (10/2014 - 10/2004)
7.	Ott, Christian: 3 articles (10/2014 - 08/2010)
8.	Pernow, John: 3 articles (01/2014 - 05/2004)
9.	Gonon, Adrian T: 3 articles (01/2014 - 05/2004)
10.	Delles, Christian: 3 articles (02/2011 - 10/2004)

Related Diseases

1.	Hyperemia 03/01/2009 - "The effect of alpha-adrenoceptor agonists and L-NMMA on cutaneous postocclusive reactive hyperemia." 07/01/2001 - "Hyperemia deteriorated skeletal muscle contractile function, although it was well preserved by l-NMMA infusion to restrict the postischemic hyperemia." 12/01/1999 - "L-NMMA produced a significant (P < 0.01) but similar (P = 0.64) reduction in peak hyperemia in the two groups. " 11/09/1999 - "L-NMMA attenuated pacing-induced hyperemia by 20% (42.4+/-5.1 versus 34.1+/-3.4 mL/min, P = 0.04) and increased minimum CVR by 33% (2.9+/-0.4 versus 3.8+/-0.5 mm Hg x mL(-1) x min(-1), P = 0.02). " 12/01/1998 - "The observation that L-NMMA reduced FBF in response to both cuff inflation and a brief contraction indicates that NO from the vascular endothelium might modulate the basal level of vascular tone and the mechanical component of the hyperemia with exercise. "
2.	Vascular System Injuries 01/16/1995 - "Similar acute potentiation of endotoxin-provoked vascular injury was observed 1 h following L-NMMA (50 mg/kg s.c.) which also increased blood pressure, indicating the inhibition of constitutive NO synthase. " 04/01/1993 - "Systemic treatment with the L-arginine antagonists, NG-monomethyl-L-arginine or nitro-L-arginine methyl ester, was also protective against vascular injury, suggesting that metabolic products of L-arginine participate in events leading to injury." 07/15/1991 - "The arginine analogue, NG-monomethyl-L-arginine (N-MeArg), which blocks NO. formation, protects against immune complex-induced vascular injury in rats. " 04/01/1994 - "7 Pretreatment with L-arginine (300 mg kg-1, s.c.) 15 min prior to the NO synthase inhibitors, reversed either the potentiation or the inhibition by L-NAME (5 mg kg-1, s.c.) or L-NMMA (50 mg kg-1, s.c.) of the LPS-induced intestinal vascular damage.8. These findings indicate that initial suppression of the constitutive NO synthase by L-NAME orL-NMMA following challenge with LPS aggravates the acute vascular injury in the ileum and colon,suggesting a defensive role of NO. By contrast, the delayed administration of NO synthase inhibitors, ata time of known expression of the inducible NO synthase, provides protection against the subsequent damage to the intestinal vasculature."
3.	Cardiogenic Shock 03/28/2000 - "The objective was to assess the safety and efficacy of L-NMMA in the treatment of cardiogenic shock. " 03/28/2000 - "L-NMMA administration in patients with cardiogenic shock is safe and has favorable clinical and hemodynamic effects." 01/01/2015 - "Considering the effectiveness of L-NMMA in decreasing tumor growth and enhancing survival rate in TNBC, we propose a targeted therapeutic clinical trial by re-purposing the pan-NOS inhibitor L-NMMA, which has been extensively investigated for cardiogenic shock as an anti-cancer therapeutic." 03/28/2000 - "L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock." 10/01/2008 - "L-NMMA therapy was associated with an excess mortality, particularly at doses > 5 mg/(kg h), in septic shock whereas the effects of a lower dose (1 mg/(kg h)) in cardiogenic shock complicating myocardial infarction were neutral. "
4.	Septic Shock (Toxic Shock Syndrome) 04/01/2009 - "Its effect of reducing cardiac index (CI) is an important reason for the increase in mortality in patients with septic shock receiving L-NMMA in a pivotal outcome trial for this indication. " 06/01/2000 - "Twenty-seven pigs were divided into three groups: seven animals received no vasopressor therapy (ETX) during endotoxic shock; ten animals were treated with NOR; and ten animals were treated with L-NMMA. " 05/01/1998 - "These results suggest that if L-NMMA has a beneficial effect on survival rates in septic shock, it is small." 05/01/1998 - "Left ventricular ejection fraction was depressed by septic shock (p = .01) and further decreased by L-NMMA (p = .02). " 04/01/1994 - "These results demonstrate an elevation in cGMP during septic shock which is attenuated by the addition of L-NMMA. "
5.	Hypotension (Low Blood Pressure) 08/01/1997 - "Infusion of L-NMMA (50 micrograms kg-1 min-1 commencing 60 min before LPS and continued throughout the experiment, n = 7) abolished the delayed hypotension and significantly attenuated the vascular hyporeactivity to NA (at 2-6 h). " 04/01/1996 - "However, reversing hypotension with L-NMMA did not improve survival in this model. " 12/26/1994 - "Although CBF remained constant with blood pressure changes in the control state (delta CBF/delta MABP of 0.037 +/- 0.155 with hypotension), CBF became dependent on blood pressure changes (delta CBF/delta MABP of 0.478 +/- 0.135, P < 0.05) during infusion of 0.35 mg/kg/min L-NMMA. " 03/01/1993 - "LCBF was significantly lower in various superficial regions such as the cerebral cortices and cerebellar cortex and in several deep brain regions in animals with haemorrhagic hypotension induced after L-NMMA infusion (the L-NMMA + HEM group) compared with animals without haemorrhagic hypotension after L-NMMA infusion (the L-NMMA group). " 01/01/1992 - "L-NMMA when given either before or after lipopolysaccharide markedly exacerbated its effects and resulted in severe hypotension, intense vasoconstriction, and increased mortality. "

Related Drugs and Biologics

1.	omega-N-Methylarginine (NG Monomethyl L Arginine)
2.	Arginine (L-Arginine)
3.	Nitric Oxide Synthase (NO Synthase)
4.	NG-Nitroarginine Methyl Ester (L-NAME)
5.	Adenosine
6.	Oxygen
7.	Nitric Oxide (Nitrogen Monoxide)
8.	Indomethacin (Indometacin)
9.	pimagedine (aminoguanidine)
10.	Mercuric Chloride (Sublimate)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Resuscitation
3.	Aftercare (After-Treatment)
4.	Intra-Arterial Infusions
5.	Ligation